AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 41 min read$IRTC

Patterson Chad sold $331K of IRTC

Patterson Chad (CHIEF COMM & PRODUCT OFFICER) sold 2,712 shares of iRhythm Holdings, Inc. (IRTC) at $122.12 ($0.33M total) on 2026-08-03.

Original reporting
SEC EDGAR · Patterson Chad
Published Aug 4, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not introduce new fundamentals, guidance, or legal/regulatory developments.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

The article does not state whether the sale was part of compensation, tax withholding, or other pre-planned arrangements; also, insider sales can be scheduled around personal needs rather than company outlook.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04, sale dated 2026-08-03

Background

The article is a Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

iRhythm Holdings insider Patterson Chad sold 2,712 shares at $122.1209 on 2026-08-03, totaling $331,191.88.

Expected impact

Likely limited near-term impact; any effect would be small and sentiment-driven.

Evidence & confidence

Form 4 shows an officer sale, but the filing provides no new business information, guidance, or regulatory/legal development. Absence of a 10b5-1 plan can raise interpretive noise, yet insider sales are often non-informational.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide signal in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be purely liquidity or tax-related, especially since the filing does not indicate any operational or financial deterioration.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Patterson Chad

    Chief Commercial and Product Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min